Schwab Charles Investment Management Inc. grew its stake in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 176,502 shares of the biotechnology company’s stock after buying an additional 8,279 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.46% of CytomX Therapeutics worth $3,726,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in the business. Bank of Montreal Can bought a new stake in shares of CytomX Therapeutics during the 4th quarter worth about $124,000. Algert Global LLC raised its position in shares of CytomX Therapeutics by 31.8% during the 3rd quarter. Algert Global LLC now owns 45,853 shares of the biotechnology company’s stock worth $833,000 after buying an additional 11,050 shares in the last quarter. Iguana Healthcare Management LLC raised its position in shares of CytomX Therapeutics by 16.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 70,000 shares of the biotechnology company’s stock worth $1,272,000 after buying an additional 10,000 shares in the last quarter. AMP Capital Investors Ltd bought a new stake in shares of CytomX Therapeutics during the 3rd quarter worth about $735,000. Finally, Allianz Asset Management GmbH bought a new stake in shares of CytomX Therapeutics during the 3rd quarter worth about $995,000. Institutional investors own 78.07% of the company’s stock.
Shares of CytomX Therapeutics stock opened at $34.00 on Monday. CytomX Therapeutics Inc has a fifty-two week low of $13.00 and a fifty-two week high of $35.00.
In related news, insider Rachel Humphrey sold 16,160 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $30.00, for a total value of $484,800.00. Following the sale, the insider now directly owns 46,394 shares in the company, valued at approximately $1,391,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Frederick W. Gluck sold 16,181 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $30.00, for a total transaction of $485,430.00. The disclosure for this sale can be found here. Insiders sold a total of 132,626 shares of company stock worth $3,709,830 over the last quarter. Insiders own 8.00% of the company’s stock.
A number of analysts have commented on the stock. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Cantor Fitzgerald set a $40.00 price target on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research report on Saturday. Citigroup began coverage on shares of CytomX Therapeutics in a research report on Friday, January 5th. They set a “buy” rating and a $40.00 price target on the stock. BidaskClub upgraded shares of CytomX Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 7th. Finally, Jefferies Group boosted their target price on shares of CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Three research analysts have rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. CytomX Therapeutics currently has an average rating of “Buy” and a consensus price target of $35.67.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/19/cytomx-therapeutics-inc-ctmx-holdings-increased-by-schwab-charles-investment-management-inc.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.